| Wednesday 8 March | |
| Amigo Holdings PLC | GM re the company's capital position |
| boohoo Group PLC | GM re adoption of the Growth Plan |
| Creo Medical Group PLC | GM re open offer shares |
| Globalworth Real Estate Investments Ltd | EGM re grant options and script dividends |
| Henderson Opportunities Trust PLC | AGM |
| Jersey Electricity PLC | AGM |
| Thursday 9 March | |
| CT Capital & Income Investment Trust PLC | AGM |
| Shoe Zone PLC | AGM |
| WAG Payment Solutions PLC | GM re proposed acquisition of Inelo |
| Friday 10 March | |
| Atrato Onsite Energy PLC | AGM |
| Malin Corp PLC | AGM |
| Mineral & Financial Investments Ltd | AGM |
| Monday 13 March | |
| BlackRock Energy & Resources Income Trust PLC | AGM |
| Hercules Site Services PLC | AGM |
| Hummingbird Resources PLC | GM re strategic investment and placement |
| Ironveld PLC | GM re second placing shares on AIM |
| Tuesday 14 March | |
| Georgia Capital PLC | GM re company's transfer from Premium to Standard listing |
| MTI Wireless Edge Ltd | AGM |
| Redx Pharma PLC | AGM |
| Copyright 2023 Alliance News Ltd. All Rights Reserved. | |
10 Mar 2022 20:31
IN BRIEF: Redx Pharma notes encouraging safety data for RXC007
(Alliance News) Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Says phase 1 data presented at Virtual Interstitial Lung Disease Drug Development summit shows novel anti-fibrotic drug candidate, RXC007, possesses excellent safety and pharmacokinetic profile in both the single and multiple dose phase. No adverse events were observed following single doses of 2-70 milligrams, dosed once or twice in a day and no serious adverse events were observed in the multiple dose phase, dosed at 50mg twice daily for 14 days, with only transient, reversible mild adverse events observed, it says.
Read more